BD has received US FDA’s emergency use authorisation and CE Mark approval for an additional molecular diagnostic test for Covid-19. Credit: BD.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Follow the latest updates of the outbreak on our timeline.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

BD has secured emergency use authorisation (EUA) from the US Food and Drug Administration (FDA) for an additional molecular diagnostic test for Covid-19 that provides results in two to three hours.

The test also secured CE Mark in Europe.

This new test, similarly to the previous Covid-19 test released by the company, runs on the BD MAX System. It is expected to scale up the testing capacity for the pandemic in the US and in other countries that accept CE Mark as regulatory approval.

BD Integrated Diagnostics president Dave Hickey said: “The new BD Covid-19 test for the BD MAX System will help increase the availability of these much-needed tests around the world. We continue to work towards a full portfolio of testing options to give health care workers choice and access to the right test for the right situation.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company’s BD MAX System is a molecular diagnostic platform that is already in use at a number of laboratories across the world. Each unit can analyse hundreds of samples over a 24-hour period.

The fully automated system can process 24 samples simultaneously. The assay is based on the same viral RNA targeting sequences and real-time PCR detection method. It is same as the test developed by the US Centers for Disease Control and Prevention (CDC).

Earlier this month, the company received US FDA emergency use authorisation for a Covid-19 diagnostic test.

This month, BD also rolled out a blood test in collaboration with BioMedomics. The test detects antibodies in the blood to confirm current or past exposure to coronavirus.